logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences to collaborate with Parexel Biotech on phase Ib/II clinical trial of first pill-based antibody treatment for Crohn’s Disease

  • Approach has the potential to be safer and more effective than current intravenous treatments
  • Clinical studies will be carried out in the US and Europe
  • Crohn’s Disease market expected to be US$4.7bn by 2025
Tiziana Life Sciences PLC -

Tiziana Life PLC (NASDAQ:TLSA; LON:TILS)  is preparing to embark on a clinical study of what would be the first orally-taken home treatment for Crohn’s Disease (CD) using a monoclonal antibody (mAb).

It is collaborating with Parexel Biotech, a subsidiary of the contract research giant Parexel, to conduct the phase Ib/II trial of a coated pill containing Foralumab, a fully-human mAb.

In doing so, researchers from Europe and the US will assess for safety, tolerability and clinical activity of escalating doses of the treatment.

Dr Howard Weiner, head of Tiziana’s scientific advisory board, called the development of a CD medication taken by mouth as a “potentially ground-breaking” alternative to immunosuppressives administered intravenously.

Severe toxicities and poor patient compliance can limit the long-term use of the latter, Tiziana pointed out. Ease of use of a pill taken at home should increase compliance by eliminating the need for infusions in a clinic or hospital, it said.

Additionally, it described using Foralumab orally as “very attractive approach” as it may provide local action to treat gut inflammation in patients with CD.

In kicking off clinical research in CD, Tiziana is entering a market that will be worth an annual US$4.7bn by 2025, but where the specific causes of the condition are still not fully understood.

However, the severe gut inflammation prevalent in people with CD is broadly known to be caused by an overactive immune system attacking the intestines, colon and other organs.

This is why immunosuppressive agents and anti-tumour necrosis factor immunotherapies represent the main treatment options.

“We believe the scientific rationale for oral treatment with Foralumab is logical to facilitate topical action at the inflamed sites in the gastrointestinal tract. This potentially ground-breaking approach for immunotherapies originated in my laboratory and was subsequently reported by other researchers in the field,” said Weiner in a statement.

Recently, Tiziana announced positive results from a phase I study showing that oral treatment with Foralumab was well-tolerated in healthy volunteers, with no drug-related safety issues even at the highest dose.

The company’s research team also successfully demonstrated that nasally-administered Foralumab was not only well-tolerated but also produced desirable immunological responses.

Both oral and nasal administration are designed to stimulate the mucosal immune system to induce disease-modifying benefits.

“We believe switching to oral, nasal and inhalational administration of mAbs from the traditional intravenous administration could potentially be transformational for the future development of immunotherapies,” said the company’s chief executive, Dr Kunwar Shailubhai.

Quick facts: Tiziana Life Sciences PLC

Price: 85 GBX

AIM:TILS
Market: AIM
Market Cap: £165.42 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tiziana Life Sciences to trial 'first ever take-home capsules' of Foralumab...

Tiziana Life Sciences PLC's (LON:TILS) (NASDAQ:TLSA) CEO Kunwar Shailubhai speaks to Proactive's Andrew Scott following the news they're collaborating with Parexel Biotech to conduct a global Phase 1b/2 trial with enteric-coated capsules of formulated Foralumab as a therapy for patients with...

2 weeks, 3 days ago

2 min read